An Extension to Assess the Effect of Expanded Dialysis on Patient Reported Symptoms Using LEVIL
Christopher McIntyreActively Recruiting
About This Study
This interventional study evaluates the impact of expanded hemodialysis (HDx) using the Theranova dialyzer on symptom burden and quality of life in patients with ESRD. Following a four-week baseline period, participants transition to the Theranova dialyzer for 24 weeks to assess if the clearance of larger middle molecules improves patient-reported outcomes. Investigators utilize the London Evaluation of Illness (LEVIL) application to collect real-time symptom data during one to three treatments per week. Secondary endpoints include changes in cognitive function via Creyos testing and assessments of sexual desire. The trial aims to determine if the biochemical advantages of HDx translate into immediate, measurable improvements in clinical symptomology.
Who Can Participate?
✓ Inclusion Criteria
- •Conventional thrice weekly HD schedule
- •Must be on chronic hemodialysis for at least 3 months
- •Age ≥18 years
- •Willing and able to give informed consent
✗ Exclusion Criteria
- •Active infection (may enroll once infection is cleared)
- •Patients receiving daily hemodialysis treatment
- •Patients currently receiving Hemodiafiltration (HDF), Hemofiltration (HF) or Isolated ultrafiltration (ISO UF) more than once in three months
- •Visual impairment
- •History of neurocognitive impairment
- •History of stroke (CVA)